THESAN PHARMACEUTICALS ANNOUNCES A $49M SERIES B FINANCING FEBRUARY 2014
SAN DIEGO, CA, Thesan Pharmaceuticals announced today the closing of a $49M Series B financing, led by Novo Ventures (a current Investor), with SV Life Sciences and Lundbeckfond Ventures joining Novartis Venture Fund in the syndicate. Thesan’s mission is the development of novel approaches for the treatment of dermatological disorders, including acne and atopic dermatitis.
Click to download press release pdf file
THESAN PHARMACEUTICALS ANNOUNCES SERIES A FUNDING CO-LED BY NOVO VENTURES AND NOVARTIS VENTURE FUNDS. OCTOBER 2012
SAN DIEGO, CA, Thesan Pharmaceuticals announced the closing of a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company will focus on the development of novel approaches for the treatment of dermatological disorders. The lead drug candidate is a topically-applied new chemical entity expected to enter the clinic in 2013.